top of page


  • WP2: Development and application of a tool to combine and use RCT and observational/registry data in economic evaluation
    Validation of a DICE simulation against a Discrete Event Simulation implemented entirely in code [] Discretely Integrated Condition Event (DICE) simulation for pharmacoeconomics [] Leveraging DICE (Discretely-Integrated Condition Event) simulation to simplify the design and implementation of hybrid models [] Adding events to a Markov Model using DICE simulation [] Cooking up a transparent model following a DICE recipe [] Economic evaluation of sequences of biological treatments for patients with moderate-to-severe Rheumatoid Arthritis and inadequate response or intolerance to Methotrexate in France [] Trusting the results of model-based economic analyses: Is there a pragmatic validation solution? [] Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–4 [] Improving transparency in decision models: Current issues and potential solutions [] Pharmacoeconomic analyses using discrete event simulation [] Advantages and disadvantages of discrete-event simulation for health economic analyses [] Discrete event simulation: the preferred technique for health economic evaluations? [] Caro JJ, Möller J. Chapter 10. DICE Simulation: A Unifying Modeling Approach for Pharmacoeonomics. Pharmacoeconomics From Theory to Practice. Arnold RJ (ed). CRC Press, Oxford, UK and Boca Raton, FL. 2nd edition 2020. Caro JJ, Möller J, Santhirapala V, Gill H, Johnston J, El-Boghdadly K, Santhirapala R, Kelly P, McGuire A (2021) Predicting Hospital Resource Use During COVID-19 Surges: A Simple but Flexible Discretely Integrated Condition Event Simulation of Individual Patient-Hospital Trajectories. Value Health. doi: 10.1016/j.jval.2021.05.023
  • WP3: Developing a costing methodology and a database of unit costs
    Špacírová Z, Epstein D, García-Mochón L et al. (2020) A general framework for classifying costing methods for economic evaluation of health care. European Journal of Health Economics 21, 529–542 [] Adjusting costs for inflation in economic evaluations of healthcare – Poster [PDF] García-Mochón L, Špacírová Z, Espín J (2021) Costing methodologies in European economic evaluation guidelines: commonalities and divergences. European Journal of Health Economics. doi: 10.1007/s10198-021-01414-w
  • WP4: The role of social costs in economic evaluations of health care decisions in Europe
    Aranda-Reneo I, Peña-Longobardo LM, Rodríguez-Sánchez B, Oliva-Moreno J, López-Bastida J. How relevant are social costs in economic evaluations? The case of Alzheimer’s disease, Jornadas de Economía de la Salud, 2019 [PDF] Peña-Longobardo LM, Rodríguez-Sánchez B, Oliva-Moreno J, Aranda-Reneo I, López-Bastida J. (2019). How relevant are social costs in economic evaluations? The case of Alzheimer’s disease. The European Journal of Health Economics, 20(8), 1207–1236. [] López-Bastida J, Aranda-Reneo I, Peña-Longobardo LM, Rodríguez-Sánchez B, Oliva-Moreno J. How relevant are social costs in economic evaluations? The case of Rare Diseases – ISPOR 2019 [Poster PDF] Juliane Andrea Duevel, Lena Hasemann, Luz Maria Peña-Longobardo, Beatriz Rodríguez-Sánchez, Isaac Aranda-Reneo, Juan Oliva-Moreno, Julio López-Bastida, Wolfgang Greiner (2020). Considering the societal perspective in economic evaluations: a systematic review in the case of depression. Health Economics Review, 2020,10 (1):32 [] López-Bastida J, Rodríguez-Sánchez B, Aranda-Reneo I, Oliva-Moreno J. Assessing the effect of including social costs in economic evaluations: A systematic review of diabetes-related interventions – ISPOR 2020 [Poster PDF] López-Bastida J, Düvel AJ, Hasemann L, Peña-Longobardo L.M, Rodríguez-Sánchez B, Aranda-Reneo I, Oliva-Moreno J, Greiner W. Considering the societal perspective in economic evaluations: a systematic review in the case of depression – ISPOR 2020 [Poster PDF] López-Bastida J, Cichetti A, Rodríguez-Sánchez B, Daugberg S, Peña-Longobardo L.M, Aranda-Reneo I, Oliva-Moreno J. Social costs in multiple sclerosis economic evaluations: do their inclusion change the results and conclusions? A systematic review – ISPOR 2020 [Poster PDF] Aranda-Reneo I, Rodríguez-Sánchez B, Peña-Longobardo LM, Oliva-Moreno J, López-Bastida J. Can the Consideration of Societal Costs Change the Recommendation of Economic Evaluations in the Field of Rare Diseases? An Empirical Analysis. Value Health. 2021 Mar;24(3):431-442. doi: 10.1016/j.jval.2020.10.014. Epub 2020 Dec 5. PMID: 33641778. [Read on PubMed] Rodriguez-Sanchez B, Aranda-Reneo I, Oliva-Moreno J, Lopez-Bastida J. Assessing the Effect of Including Social Costs in Economic Evaluations of Diabetes-Related Interventions: A Systematic Review. Clinicoecon Outcomes Res. 2021 Apr 29;13:307–334. [] Rodríguez‑Sánchez B, Daugbjerg S, Peña‑Longobardo LM, Oliva‑Moreno J, Aranda‑Reneo I, Cicchetti A, López‑Bastida J (2022) Does the inclusion of societal costs change the economic evaluations recommendations? A systematic review for multiple sclerosis disease.The European Journal of Health Economics []
  • WP5: Exploring health preferences on different subpopulation groups using EQ-5D
    Prevolnik Rupel V, Ogorevc M, IMPACT HTA HRQoL Group. et al (2021). EQ-5D-Y value set for Slovenia. PharmacoEconomics. Ludwig K, Ramos-Goñi JM, Oppe M, Kreimeier S, Greiner W (2021). To what extent do patient preferences differ from general population preferences? Value in Health. Prevolnik Rupel V, Ramos-Goñi JM, Ogorevc M, Kreimeier S, Ludwig K, Greiner W (2021). Comparison of adult and adolescent preferences toward EQ-5D-Y-3L health states. Value in Health. Kreimeier S, Mott D, Ludwig K, Greiner W (2022). EQ-5D-Y Value Set for Germany. PharmacoEconomics.
  • WP6: Methodological guidance on the analysis and interpretation of non-randomised studies to inform health economic evaluatio
    Kent S, Salcher-Konrad M, Boccia S, Bouvy JC, De Waure C, Espin J, Facey K, Nguyen M, Rejon-Parrilla JC, Jonsson P (2021). The use of nonrandomized evidence to estimate treatment effects in health technology assessment. Journal of Comparative Effectiveness Research
  • WP7: Methodological tools using multi-criteria value methods for HTA decision-making
    Oliveira MD, et al. (2019). Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art. The European Journal of Health Economics 20(6): 891–918. [] 10.1007/s10198-019-01052-3 Carlos A Bana e Costa, Ana CL Vieira, Mónica D Oliveira, João Bana e Costa. Collaborative value modelling in widely participated decision support processes. EMC-ICDSST 2019 Proceedings – Euro mini international conference on decision support system technology, 2019, 136–140 []
  • WP8: Analysis of economic evaluation methods for hospital-based assessment
    Carini E, Gabutti I, Frisicale EM, Di Pilla A, Pezzullo AM, De Waure C, Cicchetti A, Boccia S, Specchia ML (2020) Assessing hospital performance indicators. What dimensions? Evidence from an umbrella review. BMC Health Services Research. [] Grossi A, Hoxhaj I, Gabutti I, Specchia ML, Cicchetti A, Boccia S, De Waure C (2021) Hospital contextual factors affecting the implementation of health technologies: a systematic review. BMC Health Services Research. [] Gabutti I (2021). Driving health technologies towards performance: a contextualisation within the hospital setting. International Journal of Technology, Policy and Management. []
  • WP9: Expanding economic analysis for HTA: methods for measuring fiscal impact of new healthcare intervention
  • WP10: Appraisal of Orphan Medicinal Products (OMPs)
    Facey KM, Rannanheimo P, Batchelor L, Borchardt M, de Cock J (2020). Real-world evidence to support Payer/HTA decisions about highly innovative technologies in the EU – actions for stakeholders. International Journal of Technology Assessment in Health Care 1–10 [] Nicod E, Whittal A, Drummond M et al. Are supplemental appraisal/reimbursement processes needed for rare disease treatments? An international comparison of country approaches. Orphanet J Rare Dis 15, 189 (2020) [] Whittal A, Nicod E, Drummond M, Facey K. Examining the impact of different country processes for appraising rare disease treatments: a case study analysis. International Journal of Technology Assessment in Healthcare. 2021 (in press) [] Meregaglia M, Whittal A, Nicod E, Drummond M. 'Mapping' health state utility values from non-preference-based measures: a systematic literature review in rare diseases. Pharmacoeconomics. 2020 Jun;38(6):557-574. [] Meregaglia M, Nicod E, Drummond M. The estimation of health state utility values in rare diseases: overview of existing techniques. Int J Technol Assess Health Care. 2020 Oct;36(5):469-473 [] Whittal A, Meregaglia M, Nicod E. The use of patient-reported outcome measures in rare diseases and implications for health technology assessment. The Patient. 2021 Jan (open access, in press) []​ Facey K, Espin J, Kent E et al. Implementing outcomes-based managed entry agreements for rare disease treatments: Nusinersen and Tisagenlecleucel. PharmcoEconomics. July 2021. [] Xoxi E, Facey K, Cicchetti A. The evolution of AIFA registries to support managed entry agreements for orphan medicinal products in Italy. Frontiers in Pharmacology – Drugs Outcomes Research and Policy. August 2021. [] Nicod E, Meregaglia M, Whittal A, Upadhyaya S, Facey K, Drummond M (2021) Consideration of quality of life in the health technology assessments of rare disease treatments. European Journal of Health Economics. []
  • WP11: From HTA results to guidance implementation: paving the way
    Budget impact analysis of triple therapy after failure of methotrexate for the treatment of rheumatoid arthritis in France – ISPOR Europe [weblink] Annual cost of patients undergoing a total knee replacement in France – ISPOR Europe [weblink]
bottom of page